Mary-Ellen Taplin

New Capabilities

Co-principal investigator of the PROTEUS substudy

Apalutamide taken for six months before and after prostate cancer surgery cut the risk of recurrence or death by 62% compared with surgery alone in a 408-patient substudy of the PROTEUS trial. Johnson & Johnson reported the results on Oct. 24, 2026; they were presented at the ESMO Congress in Madrid and accepted for publication by European Urology.

Updated Oct 26